Introduction
============

Head and neck cancer (HNC), which encompasses malignant tumors of the larynx, pharynx, oral cavity, thyroid, and other related areas, is the 7th most common solid malignancy in the world, with approximately 686,000 new cases annually.[@b1-cmar-10-2589] Although the exact pathogenetic mechanisms of HNC are still undefined, evidence indicates that HNC carcinogenesis is a complicated, multistep, and multifactorial process, involving genetic factors, tobacco smoking, alcohol consumption, viral infection, ultraviolet radiation, lifestyle, and environmental factors.[@b2-cmar-10-2589]--[@b4-cmar-10-2589] However, although many people are exposed to these extrinsic factors, only a small proportion develop HNC,[@b5-cmar-10-2589] and a family history of HNC in first degree relatives elevates the risk.[@b6-cmar-10-2589] This indicates the existence of genetic predisposition, and suggests that certain genetic factors, such as genes involved in inflammation, might be associated with the pathogenesis of HNC. Inflammation, which is associated with DNA damage, angiogenesis, proliferation, invasion, and metastasis, may play an important role in the oncogenesis and progression of HNC.[@b7-cmar-10-2589],[@b8-cmar-10-2589] Recent studies suggest an association between HNC and increased pro-inflammatory cytokines. Among these cytokines, interleukin (IL)-8 and IL-18 have attracted increasing attention.[@b9-cmar-10-2589]--[@b11-cmar-10-2589]

As a member of the chemokine family, IL-8 is encoded by the C-X-C motif chemokine ligand 8 (CXCL8) gene, which is located on chromosome 4q-13-21 in humans. CXCL8 consists of a proximal promoter region, four exons, and three introns.[@b12-cmar-10-2589] It is produced by a wide range of healthy cells (such as neutrophils, monocytes, endothelial cells, and fibroblasts), and several types of tumor cells.[@b13-cmar-10-2589],[@b14-cmar-10-2589] Present evidence suggests that IL-8 promotes angiogenesis, tumorigenesis, tissue invasion, and metastasis.[@b15-cmar-10-2589]--[@b17-cmar-10-2589] Although CXCL8 contains several polymorphic sites, only three common polymorphisms have been reported in the coding sequence: +251 A/T, +396 G/T, and +781 C/T.[@b18-cmar-10-2589] Polymorphisms may play important roles in some cancers, including ovarian, breast, bladder, and others.[@b19-cmar-10-2589]--[@b22-cmar-10-2589] An A/T single nucleotide polymorphism (SNP) is located at position −251 of CXCL8 in the transcription start site, which is associated with IL-8 expression.[@b23-cmar-10-2589]--[@b26-cmar-10-2589] A large number of studies have investigated associations between the CXCL8 −251 A/T (rs4073) gene polymorphism and the risk of human cancers, with conflicting conclusions.[@b27-cmar-10-2589]--[@b32-cmar-10-2589]

IL-18 is also a pro-inflammatory cytokine. A member of the IL-1 super-family, it is known as an inducer of interferon-γ.[@b33-cmar-10-2589] IL-18 is produced by a number of cell types, such as activated blood and tissue monocytes/macrophages, Kupffer cells, T and B cells, osteoblasts, dendritic cells (DCs), microglia, and epithelial cells.[@b34-cmar-10-2589] IL-18 induces the activation of natural killer cells and the proliferation of activated T cells, affecting both innate and acquired immunity.[@b35-cmar-10-2589]

IL-18 is also associated with tumorigenesis, and has been reported to contribute to both anticancer and procancer processes.[@b36-cmar-10-2589]--[@b39-cmar-10-2589] The human IL-18 gene is located on chromosome 11q22.1--q22.3.[@b40-cmar-10-2589] Three SNPs in the IL-18 promoter regions have been identified that could alter IL-18 expression (−137, −607, and −656).[@b41-cmar-10-2589] However, the most commonly investigated and the most biochemically functional polymorphism is the −137 G\>C (rs187238) polymorphism. Numerous studies have reported a role for the −137 G\>C polymorphism in the susceptibility to various cancers, whereas the results of these studies mainly display that there is no association between IL-18 −137 G\>C and cancer risk,[@b42-cmar-10-2589],[@b43-cmar-10-2589] but, interestingly, in our present meta-analysis, we got a completely different result.

To our knowledge, no quantitative summary of the evidence regarding the association of CXCL8 and IL-18 polymorphisms with HNC risk has been reported, and existing studies regarding the association of CXCL8 or IL-18 with other types of cancers are contradictory. Therefore, we conducted a meta-analysis to quantitatively summarize the evidence and estimate relationships using subgroups analysis, meta regression, sensitivity analysis, and evaluation of publication bias.

Methods
=======

Publication search and inclusion criteria
-----------------------------------------

We searched the PubMed, Embase, Cochrane Library, and China National Knowledge Infrastructure databases for all potentially eligible articles up to November 31, 2017 on the association between CXCL8 and IL18 polymorphisms and HNC risk. The search terms used were "IL-8", "CXCL8", "IL-18", "polymorphism", "head and neck cancer", "nasopharyngeal cancer", "oral cancer", "laryngeal cancer", "esophageal cancer", "thyroid cancer", "tongue cancer", and "mouth neoplasm". We also screened the references of review articles and meta-analyses articles. Primary searches resulted in 176 abstracts ([Figure 1](#f1-cmar-10-2589){ref-type="fig"}). An additional six studies were added from meta-analyses and review articles, for a total of 182 studies. For inclusion, identified studies had to: (1) be case-controlled; (2) study the association between CXCL8 or IL-18 and HNC risk; (3) provide sufficient data to calculate a *P*-value and odds ratio (OR) with 95% confidence interval (CI); and (4) contain control subjects that conformed to the Hardy-Weinberg equilibrium (HWE).

Data extraction
---------------

Data were extracted independently by two investigators from studies that met the inclusion criteria. Discrepancies were resolved by discussion between the authors to reach an agreement. The following information was recorded for each study: first author, year of publication, region, cancer type, genotyping methods, source of controls, the number of cases and controls for each genotype, and HWE score in the control groups ([Table 1](#t1-cmar-10-2589){ref-type="table"}).

Statistical analysis
--------------------

Statistical analyses were performed using Stata 14.0 software (Stata Corporation, College Station, TX, USA). To evaluate the deviation of the CXCL8 and IL-18 polymorphisms from HWE, a chi-square test was used to evaluate the control subjects, in which *P*\<0.05 suggested a significant deviation from HWE. The OR corresponding to the 95% CI was used to evaluate the association between CXCL8 and IL-18 polymorphisms and HNC risk. The present study was performed using allelic, homozygote, heterozygote, dominant, and recessive models. Stratified analyses based on cancer types, ethnicity, genotyping methods, and the sources of controls and DNA samples were quantified with ORs and 95% CIs. If a cancer type was included in only one study, it was combined into the "other cancers" group. The statistical heterogeneity was evaluated using the *Q*-test and *I*^2^ statistics. When heterogeneity existed (*P*\<0.10, *I*^2^\>50%), the random effect model was used:[@b44-cmar-10-2589] otherwise, the Mantel-Haenszel method was applied to calculate ORs in a fixed-effect model.[@b45-cmar-10-2589] Stratified and meta-regression analyses were used to explore sources of heterogeneity. Moreover, sensitivity analysis was performed to assess the stability of the results by sequentially removing each study and evaluating the stability of the results. Publication bias was analyzed by Begg's funnel plot and Egger's test.[@b46-cmar-10-2589],[@b47-cmar-10-2589]

Results
=======

Study characteristics
---------------------

After a comprehensive search, 182 relevant articles were initially retrieved. After screening the titles and abstracts, 160 articles were excluded, 13 papers were duplicated, 21 papers were reviews, 80 papers were not associated with SNPs in CXCL8 or IL-18, 27 papers were not about HNC, 16 papers lacked relative data, and three papers were not consistent with HWE ([Figure 1](#f1-cmar-10-2589){ref-type="fig"}). Finally, 22 articles but 25 case-control studies (15 for CXCL8 and 10 for IL-18) covering 4731 cases and 8736 controls met our inclusion criteria ([Figure 1](#f1-cmar-10-2589){ref-type="fig"}). In terms of genotyping methods, for CXCL8, five articles used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), two articles used TaqMan assays, and five articles used other methods; for IL18, four articles used PCR-RFLP, three articles used allele specific-PCR, and three articles used other methods. The genotype distributions of the studied SNPs in the control groups agreed with HWE (*P*\>0.05). All Newcastle-Ottawa Scale (NOS) scores were greater than 5 stars, indicating good articles. The study characteristics are shown in [Table 1](#t1-cmar-10-2589){ref-type="table"}.

Quantitative synthesis
----------------------

As shown in [Tables 2](#t2-cmar-10-2589){ref-type="table"} and [3](#t3-cmar-10-2589){ref-type="table"}, when all eligible studies were pooled together, a significant association between the 137 G/C polymorphism and HNC was observed under all gene models: (C vs G: OR=1.31, 95% CI=1.09--1.57, *P*~heterogeneity~=0.002; CC vs GG: OR=1.69, 95% CI=1.20--2.38, *P*~heterogeneity~=0.175; GC vs GG: OR=1.27, 95% CI=1.01-- 1.59, *P*~heterogeneity~=0.004; GC+CC vs GG: OR=1.32, 95% CI=1.06--1.65, *P*~heterogeneity~=0.002;CC vs GG+GC: OR=1.53, 95%CI=1.13--2.06, *P*~heterogeneity~=0.321), whereas no significant association was found between the 251 A/T polymorphism and HNC risk.

Furthermore, to evaluate the effect of specific factors on the results, we performed subgroup analysis, concentrating on cancer type, ethnicity, genotyping method, and DNA sample ([Tables 2](#t2-cmar-10-2589){ref-type="table"} and [3](#t3-cmar-10-2589){ref-type="table"} and [Figure 2](#f2-cmar-10-2589){ref-type="fig"}). Stratified analysis revealed that the overall association was partly attributed to nasopharyngeal cancer for −251 A/T (AT vs TT: OR=1.39, 95%CI=1.01--1.92, *P*~heterogeneity~=0.242) and −137 G/C (C vs G: OR=1.48, 95% CI=1.20--1.83, *P*~heterogeneity~=0.222; CC vs GG: OR=2.01, 95% CI=1.30--3.10, *P*~heterogeneity~=0.598; GC vs GG: OR=1.53, 95% CI=1.22--1.93, *P*~heterogeneity~=0.365; GC+CC vs GG: OR=1.60, 95% CI=1.26--2.02, *P*~heterogeneity~=0.306; CC vs GG+GC: OR=1.72, 95% CI=1.12--2.63, *P*~heterogeneity~=0.664). In the subgroup analysis based on ethnicity, the results suggested a significantly increased risk of HNC in an African population with −251 A/T (A vs T: OR=1.63, 95% CI=1.19--2.22, *P*~heterogeneity~=NA; AA vs TT: OR=2.46, 95% CI=1.31--4.64, *P*~heterogeneity~=NA; AA+AT vs TT: OR=1.81, 95% CI=1.15--2.84, *P*~heterogeneity~=NA; AA vs AT+TT: OR=1.91, 95% CI=1.08--3.39, *P*~heterogeneity~=NA) and in an Asian population for −137 G/C (C vs G: OR=1.40, 95% CI=1.13--1.74, *P*~heterogeneity~=0.012; CC vs GG: OR=2.03, 95% CI=1.38--2.99, *P*~heterogeneity~=0.332; GC+CC vs GG: OR=1.41, 95% CI=1.06--1.86, *P*~heterogeneity~=0.004; CC vs GG+GC: OR=1.83, 95% CI=1.28--2.61, *P*~heterogeneity~= 0.469); however, no significant association was found in Asian or European populations for −251 A/T or in European or African populations for −137 G/C. In subgroup analysis by genotyping methods, a significantly elevated risk was found in the PCR-RFLP group for −137 G\>C (C vs G: OR=1.38, 95% CI=1.04--1.83, *P*~heterogeneity~=0.050; CC vs GG: OR=1.84, 95% CI=1.19--2.83, *P*~heterogeneity~=0.503; GC+CC vs GG: OR=1.44, 95% CI=1.03--2.03, *P*heterogene ity=0.053; CC vs GG+GC: OR=1.61, 95% CI=1.06--2.46, *P*~heterogeneity~=0.663), but no significant association was found for −251 A/T with any genotyping method. Stratification by the control source showed significant associations between the population-based group (C vs G: OR=1.27, 95% CI=1.02--1.59, *P*~heterogeneity~=0.016; GC+CC vs GG: OR=1.30, 95% CI=1.01--1.67, *P*~heterogeneity~=0.035) and the hospital-based group (CC vs GG: OR=2.14, 95% CI=1.11--4.12, *P*heterogene ity=0.137, CC vs GG+GC: OR=1.92, 95% CI=1.04--3.52, *P*~heterogeneity~=0.181) and −137 G\>C, whereas significantly decreased risk was found in the hospital-based group for −251 A/T (AA vs AT+TT: OR=0.54, 95% CI=0.32--0.89, *P*~heterogeneity~=0.312).

Evaluation of heterogeneity
---------------------------

There was heterogeneity among the studies in all overall comparisons and subgroup analyses for CXCL8 −251 A/T and some overall comparisons and subgroup analyses (C vs G, GC vs GG, GC/CC vs GG) for IL-18 −137 G/C. To explore the sources of heterogeneity, we performed meta-regression using publication year, cancer type, ethnicity, source of controls, sample size (≤500 and \>500 subjects) and genotyping method as covariables. The results suggested that the publication year (AA vs AT/TT: *P*=0.020; AA vs TT: *P*=0.041), source of control (AA vs AT/TT: *P*=0.024), and cancer type (AA/ATvs TT: *P*=0.047; AT vsTT: *P*=0.036) may contribute to the heterogeneity for CXCL8 −251 A/T; however, for IL18 −137 G/C, no factors contributing to the heterogeneity were found. Moreover, for CXCL8 −251 A/T, our meta-regression analyses revealed that the publication year could explain 88.38% (AA vs AT/TT), 54.62% (AA vs TT) of the τ^2^, the source of controls could explain 73.22% (AA vs AT/TT) of the τ^2^, and the cancer type could explain almost 100% (AA/AT vs TT; AT vs TT) of the τ^2^.

Sensitivity analysis
--------------------

To evaluate the sensitivity of the meta-analysis, we omitted one study at a time and checked for significant differences. There were no significant differences observed upon removal of any of the studies, indicating that the results are statistically reliable ([Figure 3](#f3-cmar-10-2589){ref-type="fig"}).

Publication bias
----------------

A Begg funnel plot was generated, and Egger's test was performed to evaluate the publication bias of the studies included in our analysis. [Figure 3](#f3-cmar-10-2589){ref-type="fig"} displays funnel plots examining the CXCL8 −251 A/T and IL-18 −137 G/C polymorphisms and cancer risk. There was marginal significance in the recessive model (CC vs GC+GG: *P*=0.048) for *IL-18* −137 G/C in the Egger's test, while no publication bias was detected in any genetic comparison for *CXCL8* −251 A/T ([Figure 4](#f4-cmar-10-2589){ref-type="fig"}).

Discussion
==========

To our knowledge, this is the first meta-analysis to assess the association of the *CXCL8* −251 A/T and *IL-18* −137 G/C polymorphisms with HNC risk. In our present study, a significantly elevated risk was observed for IL-18 −137 G/C, but no strong association between the CXCL8 −251 A/T polymorphism and HNC risk was found in the overall analysis.

Further subgroup analyses revealed that the association between *IL-18* −137 G/C and HNC risk was more predominant among nasopharyngeal cancer groups, Asian populations, studies using PCR-RFLP for genotyping, and population- and hospital-based studies. To elaborate more specifically, C alleles carriers and CC genotypes were significantly associated with an increased risk in nasopharyngeal cancer groups, Asian populations, and samples analyzed by PCR-RFLP. Moreover, an association between C allele carriers and increased risk was found in the population-based group, whereas, in the hospital-based group, an increased risk for HNC was found with the CC genotype.

Conversely, stratified analysis of CXCL8 −251 A/T provided evidence that A allele carriers and AA genotypes were associated with a significantly increased risk in African populations. Moreover, AT genotypes were associated with a significantly increased risk in the nasopharyngeal cancer group compared with the TT genotype, whereas the AA genotype was associated with a significantly decreased risk in hospital-based studies.

To some extent, our results are distinctly different from those of previous studies. Several studies in recent years have investigated these polymorphisms, with conflicting results. For CXCL8 −251 A/T, our pooled results are in accordance with some previous studies,[@b24-cmar-10-2589],[@b25-cmar-10-2589] but contrast with studies reporting a positive association between the CXCL8 −251 A/T polymorphism and cancer risk.[@b19-cmar-10-2589],[@b48-cmar-10-2589] On the other hand, for IL-18 −137 G/C, our pooled results were completely opposite to those reported by Yang et al[@b43-cmar-10-2589] and Mi et al.[@b42-cmar-10-2589]

Although the results of overall analysis are sometimes the same, similar or different trends may be found in subgroup analyses. For example, for CXCL8-251 A/T, stratification by ethnicity revealed a significant association for African populations with carriers of the A allele and homozygous AA genotypes, whereas, among non-African populations, there were no strong associations in any of the genetic models. Our results are in accordance with Gao et al,[@b28-cmar-10-2589] who also observed significantly elevated risks in African populations. However, diverse results were observed in other previous studies, Wang et al[@b22-cmar-10-2589] found that carriers of the −251 A allele among African and Asian populations were at a higher risk for cancer. Wang et al[@b27-cmar-10-2589] found that there were significant risks among Asians for both A allele carriers and AA individuals; however, no significant associations were found in non-Asian populations. On the contrary, when the *IL-18* −137 G/C, data was stratified by ethnicity, C alleles carriers and CC genotypes in Asian populations were significantly associated with an increased risk of HNC. This result is consistent with the reports of Yang et al[@b43-cmar-10-2589] and Mi et al,[@b42-cmar-10-2589] who found that C alleles and CC genotypes elevated the risk of cancers. These results indicate that *CXCL8 −251* A/T and *IL-18 −137* G/C polymorphisms may be crucial in HNC patients of specific ethnicities. The reasons for these discrepancies are not known. We hypothesize that they may be attributable to gene--environmental interactions. Variation in the allele frequency of particular polymorphisms might differ among ethnicities as a result of disparate environmental effects, and it can be inferred from the different allele distribution, in accordance with natural selection principles, that the rare allele carriers in the African populations for *CXCL8* or Asian populations for *IL-18* might be eliminated compared to in other ethnicities. This might explain why a significant association was observed in certain ethnicities, but not others. It should be noted that, for decades, nasopharyngeal cancer was more common in African and Asian populations compared with other ethnicities, consistent with the associations between nasopharyngeal cancer and the two polymorphisms studied here in these populations.[@b49-cmar-10-2589] The differences could also be due to small sample size or potential reporting bias in our study. For example, the African CXCL8 −251 A/T cohort contained approximately 329 subjects, and there is only one study in the African group.[@b50-cmar-10-2589] Therefore, it was underpowered to find causal positive or negative associations.

Cancer type was also used as a stratifying factor, and we found significantly elevated risk for nasopharyngeal cancer in the heterozygote model (AT vs TT) for CXCL8-251 A/T and in all genetic models for *IL18* −137 G/C; however, we did not find any associations with any other cancer types in any genetic models. This is consistent with the results of Gao et al[@b28-cmar-10-2589] and Wang et al.[@b22-cmar-10-2589] These findings indicate that the A allele of *CXCL8* −251 A/T and the C allele of *IL-18* −137 G/C are risk factors for developing nasopharyngeal cancer. The mechanism for these findings is not well understood.

However, a number of studies have investigated the significant biochemical functions of CXCL8 or IL-18, and the effects of particular polymorphisms. The A/T and G/C SNPs studied here are, respectively, associated with the production of CXCL8, IL-8 transcriptional activity, and the expression of IL-8 and IL-18,[@b23-cmar-10-2589]--[@b26-cmar-10-2589],[@b41-cmar-10-2589] which are associated with cancer characteristics, such as increased proliferation, invasion, and migration.[@b16-cmar-10-2589],[@b51-cmar-10-2589],[@b52-cmar-10-2589] Hence, the A allele, C allele, and CC genotype may contribute to tumorigenesis and metastasis.

Selection bias in control subject recruitment was a significant source of concern. When stratified by control source, we found significantly decreased risk among hospital-based studies for *CXCL8* −251 A/T (AA vs AT+TT), whereas, for IL-18 −137 G\>C, we observed significantly increased risk for C allele carriers (C vs G, GC+CC vs GG) among the population-based group and for the CC genotype (CC vs GG, CC vs GG+GC) among the hospital-based group. Considering that hospital-based controls lack the representativeness of population-based controls, and the amount of studies used was small, we must be cautious with our conclusions. When stratified by genotyping methods, we did not find any statistical association in any genetic models for *CXCL8* −251 A/T; however, a strong association was found in all genetic models except the heterozygote model (GC vs GG) for *IL-18* −137 G/C. This is the first report of this association in the literature.

One of the major concerns in a meta-analysis is heterogeneity among the included studies, because imprecise results may be obtained as a result of non-homogeneous data. In our study, the Q-test and *I*^2^ statistics were used to test the significance of heterogeneity. Significant heterogeneity was found in all pooled and subgroup analyses for CXCL8 −251 A/T and some for *IL-18* −137 G/C, and meta-regression was performed for the corresponding genetic models according to cancer type, ethnicity, source of controls, sample size, genotyping method, and publication year to explore its source. We found that publication year, source of controls, and cancer type were the main sources of heterogeneity for CXCL8 −251 A/T; however, these did not impact the overall summary effect. Meanwhile we did not find any factors contributing to heterogeneity in the three corresponding genetic models (C vs G, GC vs GG and GC +CC vs GG) for *IL-18* −137 G/C. This is a common phenomenon in meta-regression analyses, and is permitted.

Importantly, sensitivity analyses indicated that the estimated summary effect was robust, and did not change when individual studies were excluded.

There were several limitations to this meta-analysis. First, in the stratified analyses, we could not perform subgroup analysis by age, smoking status, alcohol consumption, treatment, and other risk factors because of insufficient data in the included studies. A more precise analysis could be conducted if these data were comprehensive. Second, tumorigenesis depends on both genetic and environmental factors, but gene--gene and gene--environment interactions were not taken into account in our meta-analysis, again because of a lack of data. Third, heterogeneity is a potential problem which may preclude the acquisition of accurate results in a meta-analysis. Significant heterogeneity was observed in some genetic models, which may have resulted from the publication year, source of controls, and cancer type. Fourth, although most controls were selected from healthy populations, a few studies selected controls from inpatients with cancer-free histories or no family history of cancer and other diseases. In addition, we used Begg's funnel plot and Egger's test to assess the publication bias, and found a marginal significance in the recessive model for *IL-18* −137 G/C by Egger's test, possibly because only published studies were included in the meta-analysis. Last, most of the subjects included were of Asian and European ancestry, with only one study for each of CXCL8 −251A/T and IL-18 −137 G/C regarding African ethnicity; therefore, potential selective bias could exist which might contribute to insufficient statistical power.

In conclusion, the present meta-analysis suggests that the *IL-18* −137 G/C polymorphism contributes to the susceptibility of HNC, especially among nasopharyngeal cancer groups, Asian populations, studies using PCR-RFLP for genotyping, and population- and hospital-based studies in some genetic comparisons. The CXCL8 −251 A/T polymorphism acted as an important genetic factor for HNC development, especially among African populations and nasopharyngeal cancer groups, and, interestingly, a decreased risk was found in the hospital-based group. However, due to the limitations mentioned above, investigations, using unbiased methods, well-matched controls, and with larger sample size and examining the effect of gene--gene and gene--environment interactions, as well as more types of interleukins, should be conducted in the future.
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###### 

Forest plot of HNC risk associated with polymorphism if CXCL8 −251 A/T and IL-18 −137 G/C. (**A**) Forest plot of association between CXCL8 −251 A/T polymorphism and HNC risk in A vs T model in ethnicity. (**B**) Forest plot of association between CXCL8 −251 A/T polymorphism and HNC risk in AT vs TT model in cancer type. (**C**) Forest plot of association between CXCL8 −251 A/T polymorphism and HNC risk in AA vs AT/TT model in source of control. (**D**) Forest plot of association between IL-18 −137 G/C polymorphism and HNC risk in GC/CC vs GG model in overall analysis. (**E**) Forest plot of association between IL18 137 G/C polymorphism and HNC risk in GC/CC vs GG model in source of control. (**F**) Forest plot of association between IL-18 −137 G/C polymorphism and HNC risk in CC vs GG model in source of control. (**G**) Forest plot of association between IL-18 −137 G/C polymorphism and HNC risk in CC vs GG model in cancer type. (**H**) Forest plot of association between IL-18 −137 G/C polymorphism and HNC risk in G vs C model in ethnicity. (**I**) Forest plot of association between IL-18 −137 G/C polymorphism and HNC risk in CC vs GG model in genotyping methods.

**Abbreviations:** HNC, head and neck cancer; OR, odds ratio; CI, confidence interval.
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![Sensitivity analysis of the overall ORs. The results were calculated through omitting each eligible study. (**A**) IL-8 −251 A/T in A versus T model; (**B**) IL-18 −137 G/C in C versus G model.\
**Note:** Superscripted a, b, c and d are parts of one study by Campa et al.[@b49-cmar-10-2589]\
**Abbreviations:** OR, odds ratio; CI, confidence interval.](cmar-10-2589Fig3){#f3-cmar-10-2589}

![Begg's funnel of the Egger's test for publication bias test. Each point represents a separate study for the indicated association. (**A**) IL-8 −251 A/T in recessive model; (**B**) IL-18 −137 G/C in recessive model.\
**Abbreviations:** OR, odds ratio; SE, standard error.](cmar-10-2589Fig4){#f4-cmar-10-2589}

###### 

Characteristics of literature included in the meta-analysis

  Reference                             Year   Region     Cancer type             Genotype methods        Sample size (case/control)   Source of control   DNA sample   Genotype---case   Genotype---control   HWE                     
  ------------------------------------- ------ ---------- ----------------------- ----------------------- ---------------------------- ------------------- ------------ ----------------- -------------------- ----- ----- ----- ----- -----
  **IL-8** −**251 A/T**                                                                                                                                                 AA                AT                   TT    AA    AT    TT    
   Shimizu et al[@b48-cmar-10-2589]     2008   Asian      Oral cancer             PCR-FRET                69/91                        Population-based    Tissue       8                 30                   31    8     45    38    YES
   Campa et al[@b49-cmar-10-2589],^a^   2007   European   Oral cancer             TaqMan                  153/725                      Population-based    Blood        41                72                   40    158   370   197   YES
   Campa et al[@b49-cmar-10-2589],^b^   2007   European   Pharynx cancer          TaqMan                  107/725                      Population-based    Blood        31                50                   26    158   370   197   YES
   Campa et al[@b49-cmar-10-2589],^c^   2007   European   Laryngeal cancer        TaqMan                  313/725                      Population-based    Blood        75                141                  97    158   370   197   YES
   Campa et al[@b49-cmar-10-2589],^d^   2007   European   Esophageal cancer       TaqMan                  171/822                      Population-based    Blood        35                93                   43    173   429   220   YES
   Ben Nasr[@b50-cmar-10-2589]          2007   African    Nasopharyngeal cancer   AS-PCR                  160/169                      Population-based    Blood        37                74                   49    23    71    75    YES
   Kietthubthew[@b51-cmar-10-2589]      2010   Asian      Oral cancer             Taq-Man                 63/99                        Population-based    Blood        10                21                   32    16    49    34    YES
   Zhang                                2008   Asian      Esophageal cancer       PCR-RFLP                320/404                      Population-based    Blood        50                175                  95    74    200   130   YES
   Liu[@b53-cmar-10-2589]               2012   Asian      Oral cancer             PCR-RFLP                270/350                      Population-based    Blood        42                131                  97    66    164   120   YES
   Wei[@b54-cmar-10-2589]               2007   Asian      Nasopharyngeal cancer   PCR-RFLP                280/290                      Population-based    Blood        54                137                  89    42    122   126   YES
   Tai[@b55-cmar-10-2589]               2007   Asian      Nasopharyngeal cancer   PCR-RFLP                105/109                      Population-based    Blood        11                52                   42    17    53    39    YES
   Liu[@b67-cmar-10-2589]               2011   Asian      Esophageal cancer       PCR-HRM                 351/384                      Hospital-based      Blood        19                192                  140   42    174   168   YES
   Hu[@b68-cmar-10-2589]                2012   Asian      Oral cancer             PCR-HRM                 142/30                       Hospital-based      Tissue       21                67                   54    5     14    11    YES
   Kiliç[@b56-cmar-10-2589]             2016   European   Thyroid cancer          PCR-RFLP                101/109                      Population-based    Blood        7                 41                   53    10    50    49    YES
   A. Savage[@b57-cmar-10-2589]         2004   Asian      Esophageal cancer       Single base extension   129/429                      Population-based    Blood        26                55                   48    75    207   147   YES
  **IL-18 −137 G/C**                                                                                                                                                    GG                GC                   CC    GG    GC    CC    
   Abdolahi[@b58-cmar-10-2589]          2015   Asian      Thyroid cancer          PCR-RFLP                105/148                      Population-based    Blood        59                33                   6     85    56    7     YES
   Babar[@b59-cmar-10-2589]             2011   European   Esophageal cancer       TaqMan                  193/1082                     Population-based    Blood        105               74                   14    582   414   86    YES
   Farhat[@b60-cmar-10-2589]            2008   African    Nasopharyngeal cancer   PCR-RFLP                163/164                      Population-based    Blood        75                73                   15    83    68    13    YES
   Asefi[@b61-cmar-10-2589]             2008   Asian      HNSCC                   AS-PCR                  111/212                      Hospital-based      Blood        65                37                   9     116   79    17    YES
   Tsai[@b62-cmar-10-2589]              2013   Asian      Oral cancer             TaqMan                  567/559                      Population-based    Blood        437               122                  8     476   78    5     YES
   Pratesi[@b63-cmar-10-2589]           2005   European   Nasopharyngeal cancer   AS-PCR                  89/130                       Population-based    Blood        43                39                   7     72    53    5     YES
   Nong[@b64-cmar-10-2589]              2009   Asian      Nasopharyngeal cancer   PCR-RFLP                250/270                      Population-based    Blood        140               88                   22    189   70    11    YES
   Wei[@b65-cmar-10-2589]               2007   Asian      Esophageal cancer       AS-PCR                  235/250                      Hospital-based      Blood        127               91                   17    176   66    8     YES
   Pan[@b69-cmar-10-2589]               2013   Asian      Nasopharyngeal cancer   PCR-RFLP                190/200                      Hospital-based      Blood        102               74                   14    139   52    9     YES
   Chung[@b66-cmar-10-2589]             2015   Asian      Thyroid cancer          Sequencing              94/260                       Hospital-based      Blood        70                18                   6     187   70    3     YES

**Note:** Superscripted a, b, c and d are parts of one study by Campa et al.[@b49-cmar-10-2589]

**Abbreviations:** HWE, Hardy Weinberg equilibrium; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; AS-PCR, alleles specific polymerase chain reaction; HNSCC, head and neck squamous cell carcinoma; PCR-HRM, polymerase chain reaction-high resolution melt; PCR-FRET, polymerase chain reaction-fluorescence resonance energy transfer.

###### 

Stratified analyses about CXCL8 −251 A/T polymorphism

  Category             n    Case/controls   A allele vs T allele (allele model) OR (95% CI), *P*, *P*h                   AA vs TT (homozygous model) OR (95% CI), *P*, *P*h                           AT vs TT (heterozygous model) OR (95% CI), *P*, *P*h                           AA+AT vs TT (dominant model) OR (95% CI), *P*, *P*h                          AA vs AT+TT (recessive model) OR (95% CI), *P*, *P*h
  -------------------- ---- --------------- ---------------------------------------------------------------------------- ---------------------------------------------------------------------------- ------------------------------------------------------------------------------ ---------------------------------------------------------------------------- ------------------------------------------------------------------------------
  Total                15   2734/5461       1.03 (0.94--1.14), 0.491, 0.039                                              1.05 (0.85--1.28), 0.672, 0.042                                              1.02 (0.88--1.19), 0.749, 0.053                                                1.04 (0.90--1.20), 0.625, 0.041                                              1.04 (0.87--1.24), 0.643, 0.056
  Cancer type                                                                                                                                                                                                                                                                                                                                                     
   Oral                                     0.96 (0.83--1.11), 0.596, 0.440                                              0.96 (0.72--1.29), 0.795, 0.580                                              0.88 (0.70--1.11), 0.280, 0.400                                                0.90 (0.72--1.11), 0.332, 0.446                                              1.04 (0.80--1.34), 0.777, 0.512
   Nasopharyngeal                           1.26 (0.89--1.79), 0.191, 0.022                                              1.49 (0.75--2.98), 0.255, 0.033                                              1.39 (1.01--1.92), 0.041, 0.242[\*](#tfn3-cmar-10-2589){ref-type="table-fn"}   1.41 (0.93--2.13), 0.104, 0.073                                              1.29 (0.76--2.18), 0.348, 0.091
   Esophageal                               0.99 (0.88--1.11), 0.897, 0.988                                              0.88 (0.67--1.17), 0.386, 0.318                                              1.14 (0.95--1.38), 0.166, 0.351                                                1.09 (0.92--1.29), 0.347, 0.723                                              0.84 (0.60--1.17), 0.300, 0.087
   Others                                   1.00 (0.82--1.23), 0.968, 0.203                                              1.06 (0.74--1.51), 0.754, 0.285                                              0.82 (0.65--1.04), 0.108, 0.622                                                0.88 (0.70--1.10), 0.262, 0.390                                              1.19 (0.93--1.53), 0.170, 0.412
  Ethnicity                                                                                                                                                                                                                                                                                                                                                       
   Asian                                    0.99 (0.87--1.12), 0.857, 0.139                                              0.91 (0.69--1.20), 0.516, 0.112                                              1.04 (0.84--1.28), 0.709, 0.058                                                1.02 (0.84--1.24), 0.854, 0.069                                              0.89 (0.70--1.14), 0.371, 0.135
   European                                 1.03 (0.92--1.15), 0.580, 0.428                                              1.09 (0.87--1.37), 0.436, 0.554                                              0.90 (0.75--1.09), 0.278, 0.616                                                0.95 (0.80--1.13), 0.581, 0.542                                              1.16 (0.96--1.40), 0.113, 0.563
   African                                  1.63 (1.19--2.22), 0.002, ---[\*](#tfn3-cmar-10-2589){ref-type="table-fn"}   2.46 (1.31--4.64), 0.005, ---[\*](#tfn3-cmar-10-2589){ref-type="table-fn"}   1.60 (0.98--2.59), 0.059, ---                                                  1.81 (1.15--2.84), 0.010, ---[\*](#tfn3-cmar-10-2589){ref-type="table-fn"}   1.91 (1.08--3.39), 0.027, ---[\*](#tfn3-cmar-10-2589){ref-type="table-fn"}
  Genotyping methods                                                                                                                                                                                                                                                                                                                                              
   PCR-RFLP                                 0.99 (0.81--1.22), 0.936, 0.028                                              0.95 (0.64--1.42), 0.811, 0.063                                              1.11 (0.88--1.41), 0.386, 0.167                                                1.06 (0.81--1.39), 0.689, 0.053                                              0.91 (0.69--1.19), 0.482, 0.252
   TaqMan                                   1.03 (0.90--1.17), 0.667, 0.287                                              1.09 (0.87--1.36), 0.458, 0.531                                              0.87 (0.69--1.11), 0.264, 0.212                                                0.93 (0.75--1.16), 0.539, 0.208                                              1.17 (0.97--1.41), 0.094, 0.676
   Others                                   1.09 (0.88--1.35), 0.435, 0.082                                              1.09 (0.61--1.94), 0.774, 0.017                                              1.12 (0.85--1.48), 0.406, 0.192                                                1.13 (0.87--1.48), 0.359, 0.170                                              1.04 (0.60--1.80), 0.887, 0.012
  Source of control                                                                                                                                                                                                                                                                                                                                               
   Population-based                         1.04 (0.94--1.17), 0.444, 0.021                                              1.11 (0.91--1.35), 0.318, 0.090                                              1.00 (0.85--1.17), 0.952, 0.053                                                1.02 (0.87--1.20), 0.793, 0.022                                              1.11 (0.95--1.29), 0.180, 0.268
   Hospital-based                           0.96 (0.78--1.18), 0.690, 0.922                                              0.59 (0.35--1.00), 0.052, 0.496                                              1.28 (0.96--1.71), 0.091, 0.514                                                1.14 (0.87--1.51), 0.342, 0.624                                              0.54 (0.32--0.89), 0.016, 0.312[\*](#tfn3-cmar-10-2589){ref-type="table-fn"}
  DNA sample                                                                                                                                                                                                                                                                                                                                                      
   Blood                                    1.04 (0.93--1.15), 0.484, 0.018                                              1.04 (0.84--1.30), 0.705, 0.019                                              1.03 (0.88--1.21), 0.691, 0.028                                                1.04 (0.89--1.22), 0.584, 0.020                                              1.04 (0.86--1.25), 0.701, 0.028
   Tissue                                   0.97 (0.67--1.39), 0.861, 0.874                                              1.04 (0.47--2.30), 0.928, 0.659                                              0.87 (0.52--1.48), 0.610, 0.751                                                0.90 (0.55--1.49), 0.687 0.893                                               1.09 (0.52--2.30), 0.812, 0.553

**Note:**

95%CI did not include 0.

**Abbreviations:** OR, odds ratio; CI, confidence interval; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; *P*h, *p*-value of the heterogenety.

###### 

Stratified analyses about IL18 −137 G/C polymorphism

  Category             n    Case/controls   C allele vs G allele (allele model) OR (95% CI), *P*, *P*h                     CC vs GG (homozygous model) OR (95% CI), *P*, *P*h                             GC vs GG (heterozygous model) OR (95% CI), *P*, *P*h                           GC+CC vs GG (dominant model) OR (95% CI), *P*, *P*h                            CC vs GG+GC (recessive model) OR (95% CI), *P*, *P*h
  -------------------- ---- --------------- ------------------------------------------------------------------------------ ------------------------------------------------------------------------------ ------------------------------------------------------------------------------ ------------------------------------------------------------------------------ ------------------------------------------------------------------------------
  Total                12   1997/3275       1.31 (1.09--1.57), 0.004, 0.002[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}   1.69 (1.20--2.38), 0.003, 0.175[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}   1.27 (1.01--1.59), 0.039, 0.004[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}   1.32 (1.06--1.65), 0.012, 0.002[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}   1.53 (1.13--2.06), 0.006, 0.321[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}
  Cancer type                                                                                                                                                                                                                                                                                                                                                           
   Thyroid                                  1.03 (0.75--1.41), 0.864, 0.657                                                2.41 (0.58--10.09), 0.227, 0.114                                               077 (0.52--1.15), 0.198, 0.603                                                 0.89 (0.61--1.29), 0.522, 0.968                                                2.60 (0.61--11.17), 0.199, 0.104
   Esophageal                               1.33 (0.70--2.50), 0.382, 0.001                                                1.56 (0.49--4.96), 0.451, 0.028                                                1.36 (0.72--2.59), 0.346, 0.011                                                1.39 (0.68--2.85), 0.363, 0.003                                                1.39 (0.55--3.52), 0.493, 0.072
   Nasopharyngeal                           1.48 (1.20--1.83), 0.000, 0.222[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}   2.01 (1.30--3.10), 0.002, 0.598[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}   1.53 (1.22--1.93), 0.000, 0.365[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}   1.60 (1.26--2.02), 0.000, 0.306[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}   1.72 (1.12--2.63), 0.012, 0.664[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}
   Others                                   1.23 (0.70--2.17), 0.478, 0.015                                                1.19 (0.60--2.35), 0.626, 0.397                                                1.23 (0.61--2.46), 0.566, 0.017                                                1.24 (0.63--2.43), 0.538, 0.015                                                1.19 (0.61--2.33), 0.614, 0.531
  Ethnicity                                                                                                                                                                                                                                                                                                                                                             
   Asian                                    1.40 (1.13--1.74), 0.002, 0.012[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}   2.03 (1.38--2.99), 0.000, 0.332[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}   1.33 (0.98--1.79), 0.066, 0.003                                                1.41 (1.06--1.86), 0.017, 0.004[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}   1.83 (1.28--2.61), 0.001, 0.469[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}
   European                                 1.08 (0.80--1.44), 0.623, 0.211                                                1.25 (0.52--3.04), 0.620, 0.166                                                1.05 (0.79--1.38), 0.752, 0.509                                                1.05 (0.81--1.37), 0.711, 0.331                                                1.19 (0.54--2.58), 0.669, 0.203
   African                                  1.15 (0.82--1.61), 0.413, ---                                                  1.28 (0.57--2.86), 0.552, ---                                                  1.19 (0.75--1.87), 0.458, ---                                                  1.20 (0.78--1.86), 0.406, ---                                                  1.18 (0.54--2.56), 0.680, ---
  Genotyping methods                                                                                                                                                                                                                                                                                                                                                    
   PCR-RFLP                                 1.38 (1.04--1.83), 0.024, 0.050[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}   1.84 (1.19--2.83), 0.006, 0.503[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}   1.39 (0.99--1.95), 0.056, 0.078                                                1.44 (1.03--2.03), 0.035, 0.053[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}   1.61 (1.06--2.46), 0.027, 0.663[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}
   AS-PCR                                   1.32 (0.85--2.03), 0.214, 0.016                                                1.81 (0.86--3.81), 0.116, 0.169                                                1.28 (0.77--2.12), 0.345, 0.034                                                1.34 (0.79--2.27), 0.281, 0.018                                                1.64 (0.94--2.87), 0.080, 0.343
   Others                                   1.21 (0.85--1.72), 0.296, 0.024                                                1.73 (0.65--4.58), 0.272, 0.063                                                1.10 (0.67--1.79), 0.713, 0.008                                                1.17 (0.76--1.79), 0.482, 0.017                                                1.73 (0.63--4.74), 0.283, 0.051
  Source of control                                                                                                                                                                                                                                                                                                                                                     
   Population-based                         1.27 (1.02--1.59), 0.035, 0.016[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}   1.47 (1.00--2.16), 0.050, 0.320                                                1.27 (1.00--1.61), 0.048, 0.075                                                1.30 (1.01--1.67), 0.038, 0.035[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}   1.35 (0.96--1.89), 0.085, 0.490
   Hospital-based                           1.36 (0.96--1.92), 0.081, 0.014                                                2.14 (1.11--4.12), 0.024, 0.137[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}   1.24 (0.74--2.08), 0.408, 0.002                                                1.34 (0.84--2.15), 0.215, 0.004                                                1.92 (1.04--3.52), 0.036, 0.181[\*](#tfn5-cmar-10-2589){ref-type="table-fn"}

**Note:**

95%CI did not include 0.

**Abbreviations:** OR, odds ratio; CI, confidence interval; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; AS-PCR, alleles specific polymerase chain reaction; *P*h, *p*-value of the heterogenety.
